Entrada Therapeutics Inc (TRDA) Stock Price, Quote & News

Company Profile

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 520 9158

Website: www.entradatx.com

Address:

One Design Center Place, Suite 17- 500, Boston, United States

prismmarketview Sep. 10 at 2:27 PM

NASDAQ: $TRDA Entrada Therapeutics awarded two $50,000 DREAMS Grants to expand access to care and support for underserved people living with Duchenne muscular dystrophy. Parent Project Muscular Dystrophy will focus on specialized care for adults and rural communities in the U.S., while Duchenne Parent Project Netherlands will expand its transition-to-adulthood coaching program. The $100,000 initiative follows World Duchenne Awareness Day and supports the theme: “Access changes lives.” https://prismmarketview.com/companies/entrada-therapeutics-inc/#news

0 · Reply

ThumsUp Aug. 31 at 6:39 PM

$TRDA bought some.

0 · Reply

0range_Hat Jun. 22 at 1:57 PM

$TRDA Keep going!

0 · Reply

nightstocker15 Jun. 15 at 2:40 PM

$TRDA let’s go back over 7 🔥💪

0 · Reply

nightstocker15 Jun. 11 at 12:04 AM

$TRDA traded this around a couple times. Getting well overdue for a nice recovery pop 🔥👀

0 · Reply

focafoca99 Jun. 10 at 8:24 PM

$TRDA concluded its 2026 annual meeting, with stockholders approving plan amendments and electing two Class II directors.

0 · Reply

Spacerobot Jun. 4 at 8:56 PM

$TRDA Gonna blast up tomorrow and into next week.

0 · Reply

SuperGreenToday Jun. 3 at 5:22 AM

$TRDA Share Price: $6.64 Contract Selected: Dec 18, 2026 $5 Calls Buy Zone: $2.26 – $2.79 Target Zone: $4.20 – $5.13 Potential Upside: 76% ROI Time to Expiration: 198 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

nightstocker15 May. 29 at 4:03 PM

$TRDA we want 10 and soon 🙌🔥🎉💪

0 · Reply

nightstocker15 May. 28 at 7:41 PM

$TRDA just nice and steady stair stepping higher 💪👀🔥

0 · Reply

Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program

Sep 9, 2026, 1:00 PM EDT - 4 days ago

Entrada Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sep 2, 2026, 4:30 PM EDT - 11 days ago

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-08-17T08:59:47.000Z - 27 days ago

Entrada Therapeutics price target raised to $11 from $10 at Roth Capital

2026-08-05T11:36:10.000Z - 5 weeks ago

Entrada Therapeutics reports Q2 EPS ($1.01), consensus ($1.04)

Aug 5, 2026, 7:00 AM EDT - 5 weeks ago

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

Aug 5, 2026, 7:00 AM EDT - 5 weeks ago

Entrada Therapeutics Earnings release: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 5 weeks ago

Entrada Therapeutics Quarterly report: Q2 2026

Aug 5, 2026, 7:00 AM EDT - 5 weeks ago

Entrada Therapeutics Slides: Corporate presentation

Jun 10, 2026, 9:30 AM EDT - 3 months ago

Entrada Therapeutics Transcript: AGM 2026

Jun 8, 2026, 8:00 AM EDT - 3 months ago

Entrada Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-08T11:22:58.000Z - 3 months ago

Entrada Therapeutics price target lowered to $17 from $20 at Guggenheim

Jun 8, 2026, 7:00 AM EDT - 3 months ago

Entrada Therapeutics Slides: Corporate presentation

Jun 3, 2026, 5:30 PM EDT - 3 months ago

Entrada Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 2, 2026, 7:00 AM EDT - 3 months ago

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study

May 19, 2026, 10:00 AM EDT - 3 months ago

Entrada Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 11, 2026, 10:40 AM EDT - 4 months ago

Entrada Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

2026-05-08T19:22:05.000Z - 4 months ago

Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital

NVS

2026-05-08T10:33:55.000Z - 4 months ago

Entrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

2026-05-07T18:55:28.000Z - 4 months ago

Entrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study

2026-05-07T12:38:27.000Z - 4 months ago

Entrada Therapeutics reports Q1 EPS (95c), consensus ($1.02)

May 7, 2026, 8:30 AM EDT - 4 months ago

Entrada Therapeutics Transcript: Study result

May 7, 2026, 8:30 AM EDT - 4 months ago

Entrada Therapeutics Press release: Study result

May 7, 2026, 8:30 AM EDT - 4 months ago

Entrada Therapeutics Slides: Study result

May 7, 2026, 7:10 AM EDT - 4 months ago

Entrada Therapeutics Reports First Quarter 2026 Financial Results

May 7, 2026, 7:04 AM EDT - 4 months ago

Entrada's Duchenne drug shown to improve muscle function in early trial

May 7, 2026, 7:00 AM EDT - 4 months ago

Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study

May 7, 2026, 7:00 AM EDT - 4 months ago

Entrada Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 months ago

Entrada Therapeutics Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 months ago

Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Entrada Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Entrada Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Entrada Therapeutics Proxy statement: Proxy filing

2026-04-06T12:05:42.000Z - 5 months ago

Entrada Therapeutics price target raised to $23 from $21 at Oppenheimer

2026-04-01T11:04:15.000Z - 5 months ago

Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-04-01T10:34:05.000Z - 5 months ago

Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-03-30T15:35:39.000Z - 5 months ago

Entrada Therapeutics management to meet with Oppenheimer

Mar 3, 2026, 2:30 PM EST - 6 months ago

Entrada Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-27T12:54:27.000Z - 6 months ago

Entrada Therapeutics price target raised to $19 from $13 at Roth Capital

2026-02-26T12:07:36.000Z - 6 months ago

Entrada Therapeutics reports Q4 EPS (94c), consensus ($1.24)

Feb 26, 2026, 7:00 AM EST - 6 months ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 7:00 AM EST - 6 months ago

Entrada Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 6 months ago

Entrada Therapeutics Annual report: Q4 2025

2026-02-17T12:10:30.000Z - 6 months ago

Entrada announces DMC recommends initiation of Cohort 2 in ELEVATE-44-201 study

Feb 17, 2026, 7:00 AM EST - 6 months ago

Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study

Feb 11, 2026, 4:00 PM EST - 7 months ago

Entrada Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

2026-02-11T11:10:24.000Z - 7 months ago

Entrada Therapeutics initiated with a Buy at Guggenheim

2026-02-10T21:27:46.000Z - 7 months ago

Entrada Therapeutics initiated with a Buy at Guggenheim

Feb 4, 2026, 7:00 AM EST - 7 months ago

Entrada Therapeutics to Present at Upcoming Investor Conferences

2026-01-28T12:35:11.000Z - 7 months ago

Entrada Therapeutics initiated with an Outperform at Oppenheimer

Jan 14, 2026, 6:45 PM EST - 8 months ago

Entrada Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 8 months ago

Entrada Therapeutics Slides: Corporate presentation

2026-01-08T12:16:10.000Z - 8 months ago

Entrada Therapeutics reports progress across development portfolio

Jan 8, 2026, 7:00 AM EST - 8 months ago

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

Dec 17, 2025, 7:00 AM EST - 9 months ago

Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-11-06T23:40:23.000Z - 10 months ago

Entrada Therapeutics price target lowered to $13 from $17 at Roth Capital

2025-11-06T12:50:18.000Z - 10 months ago

Entrada Therapeutics files $400M mixed securities shelf

Nov 6, 2025, 7:00 AM EST - 10 months ago

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 7:00 AM EST - 10 months ago

Entrada Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Entrada Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Entrada Therapeutics Registration statement: Registration Filing

Sep 25, 2025, 10:00 AM EDT - 11 months ago

Entrada Therapeutics Transcript: H.C.Wainwright @ Home Fireside Chat

Sep 25, 2025, 7:00 AM EDT - 11 months ago

Entrada Therapeutics Slides: International Conference on Muscle Wasting Presentation

Sep 8, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: Corporate Presentation

Sep 5, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

Aug 18, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: FY 2025

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: Q2 2025

Jul 21, 2025, 2:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: 6th International Caparica Conference on Splicing Presentation

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Entrada Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 11:05 AM EDT - 1 year ago

Entrada Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 12:00 PM EDT - 1 year ago

Entrada Therapeutics Slides: Corporate Presentation

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Entrada Therapeutics Proxy statement: Proxy Filing

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

BIIB

May 28, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 22, 2025, 2:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: FY 2025

May 20, 2025, 2:00 PM EDT - 1 year ago

Entrada Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 14, 2025, 2:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: 28th Annual ASGCT Meeting Presentation

May 8, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Reports First Quarter 2025 Financial Results

May 7, 2025, 6:00 PM EDT - 1 year ago

Entrada Therapeutics Earnings release: Q1 2025

May 7, 2025, 6:00 PM EDT - 1 year ago

Entrada Therapeutics Quarterly report: Q1 2025

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Entrada Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Entrada Therapeutics Proxy statement: Proxy Filing

Apr 3, 2025, 2:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: 2nd Peptide-Based Therapeutics Summit Presentation

Mar 26, 2025, 3:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: 4th Novel Conjugates Summit Presentation

Mar 26, 2025, 3:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: FY 2025

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Feb 27, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Annual report: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Slides: Q4 2024

Feb 24, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Feb 3, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Jan 30, 2025, 4:05 PM EST - 1 year ago

Azenta Announces the Election of Dipal Doshi to its Board of Directors

AZTA

Jan 15, 2025, 2:15 PM EST - 1 year ago

Entrada Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 2:15 PM EST - 1 year ago

Entrada Therapeutics Slides: FY 2025

Dec 18, 2024, 7:00 AM EST - 1 year ago

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 12:30 PM EST - 1 year ago

Entrada Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 5, 2024, 7:00 AM EST - 1 year ago

Entrada Therapeutics Quarterly report: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Entrada Therapeutics Earnings release: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Entrada Therapeutics Slides: Q3 2024

Oct 9, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

Sep 24, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

Sep 17, 2024, 8:30 AM EDT - 1 year ago

āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

Sep 9, 2024, 12:30 PM EDT - 2 years ago

Entrada Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Sep 6, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Slides: Corporate Presentation

Jun 24, 2024, 7:15 AM EDT - 2 years ago

Entrada Therapeutics Announces $100 Million Registered Direct Offering

Jun 24, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Slides: Corporate Presentation

Jun 24, 2024, 6:00 AM EDT - 2 years ago

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

Jun 10, 2024, 4:00 PM EDT - 2 years ago

Entrada Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 16, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 7, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports First Quarter 2024 Financial Results

May 7, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Quarterly report: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Earnings release: Q1 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Entrada Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Entrada Therapeutics Proxy statement: Proxy Filing

Apr 19, 2024, 8:00 AM EDT - 2 years ago

Entrada Therapeutics Proxy statement: Proxy Filing

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Entrada Therapeutics Earnings release: Q4 2023

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Entrada Therapeutics Annual report: Q4 2023

Mar 13, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Nov 22, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy

Nov 7, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics Quarterly report: Q3 2023

Nov 7, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics Earnings release: Q3 2023

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

Aug 8, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

Aug 8, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Quarterly report: Q2 2023

Aug 8, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Earnings release: Q2 2023

Jun 14, 2023, 1:40 PM EDT - 3 years ago

Entrada Therapeutics Transcript: Goldman Sachs 44th Annual Global Healthcare Conference

Jun 6, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

May 10, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports First Quarter 2023 Financial Results

May 10, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Quarterly report: Q1 2023

May 10, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Earnings release: Q1 2023

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Entrada Therapeutics Proxy statement: Proxy Filing

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Entrada Therapeutics Proxy statement: Proxy Filing

Apr 4, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

Mar 29, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

Mar 6, 2023, 7:00 AM EST - 3 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 6, 2023, 7:00 AM EST - 3 years ago

Entrada Therapeutics Earnings release: Q4 2022

Mar 6, 2023, 7:00 AM EST - 3 years ago

Entrada Therapeutics Annual report: Q4 2022

Feb 27, 2023, 7:00 AM EST - 3 years ago

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

prismmarketview Sep. 10 at 2:27 PM

0 · Reply

ThumsUp Aug. 31 at 6:39 PM

$TRDA bought some.

0 · Reply

0range_Hat Jun. 22 at 1:57 PM

$TRDA Keep going!

0 · Reply

nightstocker15 Jun. 15 at 2:40 PM

$TRDA let’s go back over 7 🔥💪

0 · Reply

nightstocker15 Jun. 11 at 12:04 AM

$TRDA traded this around a couple times. Getting well overdue for a nice recovery pop 🔥👀

0 · Reply

focafoca99 Jun. 10 at 8:24 PM

$TRDA concluded its 2026 annual meeting, with stockholders approving plan amendments and electing two Class II directors.

0 · Reply

Spacerobot Jun. 4 at 8:56 PM

$TRDA Gonna blast up tomorrow and into next week.

0 · Reply

SuperGreenToday Jun. 3 at 5:22 AM

0 · Reply

nightstocker15 May. 29 at 4:03 PM

$TRDA we want 10 and soon 🙌🔥🎉💪

0 · Reply

nightstocker15 May. 28 at 7:41 PM

$TRDA just nice and steady stair stepping higher 💪👀🔥

0 · Reply

ScorpionScarlet May. 22 at 2:35 PM

$TRDA another beauty 🍾🥂💕💸

0 · Reply

nightstocker15 May. 22 at 2:21 PM

$TRDA break through 7 next 💪🎉

0 · Reply

nightstocker15 May. 21 at 9:36 PM

$TRDA insiders loading up, wonder if we start to see more rolling in! Take advantage! strong buy 💪👀🙌

0 · Reply

ScorpionScarlet May. 21 at 8:40 PM

$TRDA oh director bought shares 💕 something good will happen🥳💰

0 · Reply

nightstocker15 May. 21 at 3:31 PM

$TRDA curling up 👀! Let’s start the move to 10 💪

0 · Reply

ScorpionScarlet May. 21 at 1:47 PM

$TRDA slowly going up when shorts asleep😆🥳💕

0 · Reply

theBigDollarski May. 19 at 3:03 PM

$TRDA started a position at 5.70, a rather large position.

0 · Reply

nightstocker15 May. 14 at 5:55 PM

$IPHA hell of a move! Keep an eye on $TRDA conference next Tuesday 👀🔥 and way oversold! Trades thin and can run hard! 💪

0 · Reply

nightstocker15 May. 14 at 3:39 PM

$TRDA drop on low volume, buying here 💪

0 · Reply

MarketBeat May. 9 at 6:07 AM

Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile $TRDA https://www.marketbeat.com/instant-alerts/entrada-t

0 · Reply

Youngmoney22choppa May. 7 at 9:17 PM

$TRDA well considering I swung trade it for a profit today I think I’m fine

0 · Reply

NotHopeJustFacts May. 7 at 8:43 PM

$TRDA what a POS, this would go BK in no time, smart money know this and this is why 50% with not so bad news, classic biotech scam

0 · Reply

Market Cap	264.77M
Revenue (ttm)	25.42M
Net Income (ttm)	-143.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-565.50%
Debt to Equity Ratio	0.00

Volume	291,800
Avg Vol	371,254
Day's Range	N/A - N/A
Shares Out	38.94M
Stochastic %K	36%
Beta	-0.25
Analysts	Strong Sell
Price Target	$17.00